Contact Search Sitemap Deutsch
  Bayer Links
  Bayer Global
  Investor Relations
  Financial Reports 2005
  General Conditions of Use
  Privacy Statement
  Imprint
  Technical Details
 
Sitemap  
 
 Financial Report
Bayer Group Key Data
Ten-Year Financial
Summary

 
 Stock
 
 
 Bayer Group
Chairman's Letter
Corporate Structure
Credo
Board of Management
Report of the Supervisory
Board
Corporate Governance
Sustainability &
Responsibility
Governance Bodies
Supervisory Board
Board of Management
Group Leadership Circle
Organization Chart

 
 Science For A Better Life
Bayer: Science For
A Better Life
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience

 
 Services
Service Overview
Download Center
Order
Index from A to Z
Glossary

 
  
 Management Report
Overview of Sales,
Earnings and Financial
Position
Operating Environment
Performance by Subgroup
and Segment
Performance by Region
Value Management
Liquidity and
Capital Resources
Earnings Performance
Asset and Capital
Structure
Proposal for Distribution of
the Profit
Employees
Procurement and
Distribution
Research and
Development
Sustainable Development
Corporate Social
Responsibility
Risk Management
Subsequent Events
Future Perspectives
Economic Outlook
Business Strategy
Objectives for 2006

 
 Highlights 2005/2006
Awards
Triple-i
New fuel cell
production facility
Pharmaceuticals
business strenghened
U.S. approval for Nexavar
Innovative fungicide
Dr. Wolfgang Plischke
appointed to Management
Board
Promising anti-
thrombosis drug
Formulation technology
for cereal herbicides
New manufacturing
process for carbon
nanotubes
Bayer and UNEP
Bayer acquires
Icon Genetics AG
25 billion tablets
produced in Bitterfeld
New production facility
in China
Research to protect
drinking water
  
 Financial Statements
Management's Statement
of Responsibility
Independent Auditor's
Report
Statements of Income
Balance Sheets
Statements of Cash Flows
Statements of Recognized
Income and Expense
Notes
Key Data by
Segment and Region
General Information
Effects of new
accounting
pronouncements
Basic principles of
the consolidated
financial statements
Consolidation methods
Foreign currency
translation
Basic recognition and
valuation priciples
Cash flow statement
Impairment testing
Critical accounting
policies
Segment reporting
Changes in the
Bayer Group
Scope of consolidation
Acquisitions and
divestments
Notes to the
Statements of Income
8. - 15.
16. - 18.
Notes to the
Balance Sheets
19. - 21.
22. - 27.
28.
29.
30. - 32.
33. - 34.
35.
Notes to the Statements
of Cash Flows
Other information
 
 

 
top
Last updated: March 06, 2006 E-mail this page Copyright © Bayer AG
 
 
Print page
Services
Order printed edition
Index from A to Z
Glossary
Calendar
Newsletter
SMS Service
In order to view the documents you require the free software Adobe Acrobat Reader.
Download Acrobat Reader